60 filings
8-K
SABS
SAB Biotherapeutics Inc
15 Apr 24
Regulation FD Disclosure
5:15pm
8-K
SABS
SAB Biotherapeutics Inc
29 Mar 24
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
9:35am
8-K
SABS
SAB Biotherapeutics Inc
8 Mar 24
Entry into a Material Definitive Agreement
4:30pm
8-K
SABS
SAB Biotherapeutics Inc
2 Feb 24
SAB Biotherapeutics Announces Executive Leadership Change
7:53am
8-K
SABS
SAB Biotherapeutics Inc
26 Jan 24
Entry into a Material Definitive Agreement
4:15pm
8-K
layjlzizg5k
25 Jan 24
Other Events
5:00pm
8-K
4f78fce740k
19 Jan 24
Regulation FD Disclosure
4:21pm
8-K
58drpwv h4nq6vpttw5p
3 Jan 24
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
9:00am
8-K
22e38kp
29 Nov 23
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying
7:40am
8-K
90t 7la7pi6gzgc
22 Nov 23
Amendments to Articles of Incorporation or Bylaws
4:45pm
8-K
of1xau nh
20 Nov 23
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
5:00pm
8-K/A
w8c 2b5p8888luqa
14 Nov 23
Unregistered Sales of Equity Securities
4:31pm
8-K
5t5oau4
27 Oct 23
Entry into a Material Definitive Agreement
5:00pm
8-K
acy2 xg532
2 Oct 23
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
4:10pm
8-K
s2mr7
21 Aug 23
Changes in Registrant's Certifying Accountant
8:25am
8-K
g4bux4 2rxy
31 Jul 23
Changes in Registrant's Certifying Accountant
4:43pm
8-K
yt3r3msg0in jhj80
3 Jul 23
Submission of Matters to a Vote of Security Holders
1:20pm
8-K
4ugf0xp0qk7io1
21 Jun 23
Regulation FD Disclosure
8:50am
8-K
c6g3 9uep
14 Jun 23
Regulation FD Disclosure
8:53am
8-K
8m84u0q0 8kmng
12 May 23
Regulation FD Disclosure
5:17pm